Hikal Limited · NSE:HIKAL
Hikal — Q1 FY22 Earnings Presentation
24 slides from Hikal's earnings presentation, Aug 5, 2021
Slide 1: Exchange filing cover letter for results presentation
HfJ<AL August 5, 2021 Dept. of Corporate Services, Listing Department, BSE Ltd., National Stock Exchange of India Ltd., P J Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai-400 001. Mumbai 400051. BSE Scrip Code : 524735 NSE Symbol : HIKAL Dear Sir/ Madam, Subject: R
Slide 2: Results Presentation – Q1 FY22
Results Presentation – Q1 FY22
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and
Slide 4: CMD's Message
CMD’s Message “I am happy to report that we have recorded a strong performance in Q1 despite the challenges posed by the second wave of the COVID-19 pandemic. We have continued the growth trajectory that the company had established over the past two quarters. Our Pharmaceuticals business has perform
Slide 5: Hikal's Contribution Towards the Fight Against COVID-19
Hikal’s Contribution Towards the Fight Against COVID-19 COVID-19 related work at Hikal Sites COVID-19 related CSR work by Hikal • Company-wide vaccination drive covered nearly 85% of • Supported the CII Foundation in providing 10,000 N95 total employees (including contractual) with first dose masks
Slide 6: Quarterly Financials Highlights
Quarterly Financials Highlights
Slide 7: Consolidated Profit & Loss – Q1 FY22
Consolidated Profit & Loss – Q1 FY22 Particulars (Rs. Crore) Q1 FY22 Q1 FY21 Y-o-Y Q4 FY21 Q-o-Q Net Sales 457 353 29% 532 -14% Expenditure 361 300 423 EBITDA 96 53 82% 109 -12% Margin 21.0% 14.9% 20.5% Other Income 3 1 3 Depreciation 23 21 22 Finance Costs 8 10 10 PBT 68 23 200% 81 -15% Tax 18 8 30
Slide 8: Revenue – Q1 FY22 Rs. 457 Crore
Positive momentum from last two quarters continued in Q1 further strengthening our growth trajectory Revenue – Q1 FY22 EBITDA – Q1 FY22 EBITDA Margin – Q1 FY22 Rs. 457 Crore Rs. 96 Crore 21.0% YoY QoQ YoY QoQ YoY QoQ 29% -14% 82% -12% 606 bps 46 bps PAT – Q1 FY22 EPS – Q1 FY22 Rs. 51 Crore Rs 4.1 Yo
Slide 9: Quarterly Performance Highlights
Quarterly Performance Highlights Revenue +29% 532 Performance Highlights 457 353 • Revenue recorded an increase of 29% YoY • Higher sales of existing products and addition of new products • Strong performance in own generics as well as CDMO segment Q1FY21 Q4FY21 Q1FY22 • EBITDA increased to Rs 96 Cr
Slide 10: Quarterly Performance Highlights – Pharmaceuticals
Quarterly Performance Highlights – Pharmaceuticals Revenue +28% Pharmaceuticals - Performance Highlights 298 274 • Revenue recorded an increase of 28% YoY 214 • Strong growth in both own generics and CDMO segment • EBIT increased to Rs 48 Crore, growth of 121% YoY • Favorable product mix resulting i
Slide 11: Quarterly Performance Highlights – Crop Protection
Quarterly Performance Highlights – Crop Protection Revenue +31% Crop Protection - Performance Highlights 235 • Revenue recorded an increase of 31% YoY 183 • Increased sales volume of existing as well as new products 139 • EBIT of Rs 32 Crore, growth of 89% YoY • Higher operational leverage due to in
Slide 12: Quarterly Financial Highlights
Quarterly Financial Highlights Consolidated Revenue Consolidated EBITDA Consolidated PAT +236% +29% +82% 532 109 51 51 463 457 96 91 40 372 353 70 27 53 15 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Rs. Crore © Hikal Limited
Slide 13: Quarterly Segmental Highlights
Quarterly Segmental Highlights Pharmaceuticals Revenue Crop Protection Revenue +28% 298 +31% 279 269 274 235 214 194 183 139 93 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Pharmaceuticals EBIT Crop Protection EBIT +121% +89% 50 51 48 48 48 31 32 22 17 8 Q1FY21 Q2FY21 Q3FY21
Slide 14: Annual Financials Highlights
Annual Financials Highlights
Slide 15: Financial Highlights - Annual
Financial Highlights - Annual Revenue – FY21 EBITDA – FY21 EBITDA Margin – FY21 Rs. 1,720 Crore Rs. 323 Crore 18.8% FY17-21 FY17-21 YoY YoY YoY CAGR CAGR 14% 18% 65 bps 14% 13% PAT – FY21 EPS – FY21 Rs. 133 Crore Rs 10.80 FY17-21 FY17-21 YoY YoY CAGR CAGR 58% 58% 19% 19% © Hikal Limited
Slide 16: Annual Performance Highlights
Annual Performance Highlights Revenue EBITDA PAT +14% +18% +58% 1,720 323 133 1,507 273 84 FY20 FY21 FY20 FY21 FY20 FY21 Pharmaceuticals Division Crop Protection Division +19% +7% 1,060 620 661 887 Revenue Revenue FY20 FY21 FY20 FY21 +33% +4% 170 100 103 128 EBIT EBIT Rs. Crore FY20 FY21 FY20 FY21 ©
Slide 17: Yearly Financial Highlights
Yearly Financial Highlights Consolidated Revenue Consolidated EBITDA Consolidated PAT +14% +13% 1,720 323 133 1,590 298 1,507 +19% 273 1,300 242 103 197 84 1,034 77 67 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 Rs. Crore © Hikal Limited
Slide 18: Yearly Segmental Highlights
Yearly Segmental Highlights Pharmaceuticals Revenue Crop Protection Revenue +12% +15% 1,060 651 661 620 939 887 547 753 423 611 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 Pharmaceuticals EBIT Crop Protection EBIT +8% +21% 170 112 100 103 129 128 87 75 99 79 FY17 FY18 FY19 FY20 FY21 FY17 FY18
Slide 19: Sales Break-Up
Sales Break-Up Pharmaceuticals Revenue Break-Up Crop Protection Revenue Break-Up CDMO CDMO Own products Own products 41.2% 54.0% 69.0% 76.7% 58.8% 46.0% 31.0% 23.3% FY20 FY21 FY20 FY21 © Hikal Limited
Slide 20: Consolidated Profit & Loss – Full Year
Consolidated Profit & Loss – Full Year Particulars (Rs. Crore) FY21 FY20 Y-o-Y Net Sales 1,720 1,507 14% Expenditure 1,397 1,234 EBITDA 323 273 18% Margin 18.8% 18.1% Other Income 5 4 Depreciation 85 82 Finance Costs 36 52 Exceptional Item - 15 PBT 206 127 63% Tax 73 42 Net Profit 133 84 58% Margin
Slide 21: Ratio Analysis
Ratio Analysis ROE ROCE 15.2% 14.5% 16.1% 15.2% 12.0% 11.3% 12.8% 10.7% 12.5% 11.1% FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 Net Debt / Equity Net Debt / EBITDA 0.9 0.9 2.9 0.8 2.5 0.7 2.1 2.1 0.6 1.8 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 © Hikal Limited
Slide 22: Annual Dividend Payout
Annual Dividend Payout Dividend Payout 21% 19% 14% 24% 22% 18% 19% 17% 20% 19% including DDT 10.80 EPS DPS 8.36 6.85 6.27 5.70 5.18 4.39 3.28 3.35 2.05 2.00 1.20 1.00 1.00 1.20 1.20 1.20 1.20 0.90 0.50 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 ▪ The above dividend is based on Face Value of R
Slide 23: Contact Us
Contact Us Company : Investor Relations Advisors : Hikal Limited Strategic Growth Advisors Pvt. Ltd. CIN: L24200MH1988PTC048028 CIN: U74140MH2010PTC204285 Mr Kuldeep Jain Mr. Jigar Kavaiya +91-9920602034 Kuldeep_jain@hikal.com jigar.kavaiya@sgapl.net www.hikal.com www.sgapl.net © Hikal Limited
Slide 24: HIKAL
HIKAL